Cancer NetworkOriginal article
<![CDATA[FLAURA2 Survival and Limits of Cross-Trial Comparison]]>
Phase 3positiveosimertinibPositive
AI Analysis
Summary
Final overall survival data from the phase 3 FLAURA2 study demonstrates osimertinib plus chemotherapy achieved 47.5+ months survival versus approximately 38 months for osimertinib alone in EGFR-mutated advanced NSCLC.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Final overall survival data from FLAURA2 study showed osimertinib plus chemotherapy achieved 47.5+ months versus approximately 38 months for osimertinib alone
Importance:7/10
Sentiment:
0.60
oncologyNSCLCEGFR-mutatedsurvival dataPhase 3
Read the original article
Published by Cancer Network on September 28, 2026 12:05 PM